Pfizer discontinues Phase IIb of S. aureus vaccine

By Brian Moy | Jan 4, 2019 | 5:01 AM GMT

Pfizer Inc. (NYSE:PFE) discontinued the Phase IIb STRIVE trial of PF-06290510 to prevent postoperative invasive Staphylococcus aureus infections in patients